OmanDocSign in

Curriculum · Cardiovascular and Hypertension

Hypertension in the patient with diabetes

What it is

In an adult with hypertension, lifestyle interventions run throughout, and the blood pressure goal and the first drug are set by age, diabetes, and chronic kidney disease (CKD).

A goal of 140/90 mm Hg comes from JNC 8, and 130/80 mm Hg from the more recent American College of Cardiology and American Heart Association recommendations. For blood pressure control in CKD the two pages do not give the same systolic number: one sets the goal at SBP <140 mm Hg and DBP <90 mm Hg for CKD present with or without diabetes, all ages and all races, while the other sets the systolic target at SBP <120 and adds that higher targets, for example <130-140 mm Hg, are considered for selected patients. A second target, set by age rather than by diabetes alone, runs alongside it: in the patient with diabetes, pharmacologic therapy is initiated in addition to lifestyle therapy once the blood pressure is confirmed at 140/90 mmHg or above, and the aim is 130/80 or lower in patients less than 65 years of age and in those at high risk for CVD, and below 140/80 in elderly patients, that is 65 years and over, if tolerated. Hypertension, defined as a BP of 140/90 mmHg or more, is an extremely common co-morbid condition in patients with diabetes, and the blood pressure should be checked during each clinic visit. It substantially increases the risk of both macro- and micro-vascular complications, including stroke, coronary artery disease, peripheral vascular disease, retinopathy and nephropathy.

How it is treated

Diabetes moves ACEI and ARB to the front. Offer an ACE inhibitor or an ARB to an adult starting step 1 antihypertensive treatment who has type 2 diabetes, of any age or family origin, or who is under 55 and not of black African or African-Caribbean family origin. If an ACE inhibitor is not tolerated, for example because of cough, offer an ARB, and do not combine an ACE inhibitor with an ARB. ACE inhibitors are initiated for renal protection in adults with diabetes mellitus, hypertension and microalbuminuria, where they reduce the decline in renal function. They decrease urinary albumin loss and are an essential part of treatment for diabetics with hypertension, and should be started before fixed albuminuria is present. Beta blockers are no longer recommended for first-line treatment. In the diabetic without CKD the initial choice forks in two: nonblack, a thiazide-type diuretic or ACEI or ARB or CCB, alone or in combination; black, a thiazide-type diuretic or CCB, alone or in combination, so ACEI and ARB are not among the initial choices there. Step 2 adds a CCB or a thiazide-like diuretic. Common agents are lisinopril and captopril, losartan and valsartan, amlodipine, nifedipine and verapamil, and the selective beta blockers bisoprolol and atenolol. For patients with persistent albuminuria the initial treatment should include a RAS blocker to reduce the risk of progressive kidney disease, but combinations of ACE inhibitors and angiotensin receptor blockers should not be used; where both have been given, serum creatinine, estimated glomerular filtration rate and serum potassium are checked two weeks after initiation or titration and then annually. So when a patient already taking an ACE inhibitor is still above target, the drug to add comes from another class, not a second blocker of the same kind. And when three drugs at full dose leave the pressure high, confirm resistant hypertension with ABPM or HBPM, check for postural hypotension and discuss adherence, then consider expert advice or add low-dose spironolactone if the blood potassium level is 4.5 mmol/l or below, or an alpha-blocker or beta-blocker if it is above 4.5. Initial treatment should include any of these drug classes: ACE inhibitors, angiotensin receptor blockers, thiazide-like diuretics, or dihydropyridine calcium channel blockers. Many people will require two or more drugs to reach the recommended BP target, such as an ACE inhibitor or an ARB combined with a calcium channel blocker or a diuretic. The reason an ACE inhibitor or an ARB comes first in the diabetic with microalbuminuria is that it protects the kidney by lowering the intraglomerular pressure while it also treats the hypertension, and so reduces progression to CKD. The traps are to start a beta-blocker or a CCB first, to pass over the microalbuminuria, and to treat the BP only and not the kidneys. In pregnant women with diabetes and chronic hypertension, a blood pressure target of 120-135/80-85 mmHg is suggested, in the interest of long-term maternal health and to minimize the risk of impaired fetal growth, and ACE inhibitors and ARBs are contraindicated during pregnancy.